Alphatec Holdings (ATEC) Aperçu de l'action
Alphatec Holdings, Inc. est une société de technologie médicale qui conçoit, développe et fait progresser les technologies pour le traitement chirurgical des troubles de la colonne vertébrale aux États-Unis et dans le monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
ATEC Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alphatec Holdings, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$9.76 |
| Plus haut sur 52 semaines | US$23.29 |
| Plus bas sur 52 semaines | US$9.11 |
| Bêta | 1.12 |
| Variation sur 1 mois | -10.29% |
| Variation sur 3 mois | -34.19% |
| Variation sur 1 an | -11.75% |
| Variation sur 3 ans | -33.42% |
| Variation sur 5 ans | -36.13% |
| Évolution depuis l'introduction en bourse | -90.94% |
Nouvelles et mises à jour récentes
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.Recent updates
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).Alphatec Holdings: Buy On Solid Results And Outlook
Feb 27ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
Oct 05Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Jul 28Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
Jul 09Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
May 11Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
Apr 20Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Mar 01Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Jan 18Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Dec 19Alphatec: A Big Recovery
Dec 03Alphatec Holdings, Inc. (NASDAQ:ATEC) Soars 50% But It's A Story Of Risk Vs Reward
Nov 01Positive Sentiment Still Eludes Alphatec Holdings, Inc. (NASDAQ:ATEC) Following 38% Share Price Slump
Aug 29We Think Alphatec Holdings (NASDAQ:ATEC) Has A Fair Chunk Of Debt
Aug 28Alphatec: Creating Some Real Back Pain For Its Shareholders
Aug 05Potential Upside For Alphatec Holdings, Inc. (NASDAQ:ATEC) Not Without Risk
Jul 15Rendement pour les actionnaires
| ATEC | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -4.4% | -5.3% | -0.2% |
| 1Y | -11.8% | -18.1% | 27.6% |
Rendement vs Industrie: ATEC a dépassé le secteur US Medical Equipment qui a rapporté -18.1 % au cours de l'année écoulée.
Rendement vs marché: ATEC a sous-performé le marché US qui a rapporté 27.6 % au cours de l'année écoulée.
Volatilité des prix
| ATEC volatility | |
|---|---|
| ATEC Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Cours de l'action stable: ATEC n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ATEC ( 8% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1990 | 913 | Pat Miles | www.atecspine.com |
Alphatec Holdings, Inc. est une société de technologie médicale qui conçoit, développe et fait progresser les technologies pour le traitement chirurgical des troubles de la colonne vertébrale aux États-Unis et dans le monde. La société fabrique et vend des implants, des instruments, des équipements d'imagerie et des pièces détachées. Elle propose la plateforme de produits Alpha InformatiX, qui comprend le système d'imagerie EOS, qui fournit une imagerie du corps entier ; le système SafeOp Neural InformatiX, qui automatise la surveillance électromyographique, du potentiel évoqué somatosensoriel et du potentiel évoqué moteur ; et Valence, un système peropératoire qui intègre la navigation et la robotique dans les procédures rachidiennes, ainsi que les systèmes Sigma Prone TransPsoas (PTP) Access et PTP Patient Positioning Systems.
Alphatec Holdings, Inc. Résumé des fondamentaux
| ATEC statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.41b |
| Bénéfices(TTM) | -US$143.36m |
| Recettes(TTM) | US$764.16m |
1.9x
Ratio P/S-10.3x
Ratio P/ELe site ATEC est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ATEC compte de résultat (TTM) | |
|---|---|
| Recettes | US$764.16m |
| Coût des recettes | US$232.27m |
| Marge brute | US$531.89m |
| Autres dépenses | US$675.25m |
| Les revenus | -US$143.36m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
May 05, 2026
| Résultat par action (EPS) | -0.95 |
| Marge brute | 69.60% |
| Marge bénéficiaire nette | -18.76% |
| Ratio dettes/capitaux propres | 1,570.8% |
Quelles ont été les performances à long terme de ATEC?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/04/30 00:13 |
| Cours de l'action en fin de journée | 2026/04/30 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Alphatec Holdings, Inc. est couverte par 26 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Caitlin Cronin | Canaccord Genuity |
| Tao Levy | Deutsche Bank |